CHAOSTOCOSMOS

Thursday, 29 January 2015

“Pharmaceutical Grade” Low Dose Naltrexone Now Available for ME/CFS and Fibromyalgia Patients

Immune Therapeutics has the exclusive rights to develop LDN for a wide variety of disorders including Crohn’s Disease, IBS, prostate cancer, lymphomas,  infectious diseases such as chronic herpes virus infections, Fibromyalgia, Parkinson, chronic infections due to the Epstein-Barr virus, and chronic inflammatory conditions including chronic fatigue syndrome.

"Pharmaceutical Grade" Low Dose Naltrexone Now Available for ME/CFS and Fibromyalgia Patients

No comments:

Related Posts Plugin for WordPress, Blogger...
^ Top